CD101-AS1: A promising drug target and biomarker for cancer treatment
CD101-AS1: A promising drug target and biomarker for cancer treatment
Abstract:
CD101-AS1 is a unique protein that has been identified as a potential drug target and biomarker for cancer treatment. Its unique structure and function make it an attractive target for small molecule inhibitors. This article will discuss the CD101-AS1 protein, its function in cancer, and the potential for its use as a drug target and biomarker.
Introduction:
CD101-AS1 is a protein that is expressed in a variety of tissues and cells, including the brain, heart, and gastrointestinal tract. It is a member of the CD101 family, which is known for its role in various cellular processes, including cell signaling and inflammation. CD101-AS1 has been shown to play a role in cancer progression and metastasis.
CD101-AS1 functions as an oncogene
CD101-AS1 has been shown to function as an oncogene in various cancer types. Its role in cancer development is related to its ability to promote the formation of cancer stem cells. CD101-AS1 has been shown to induce the stem-like properties of cancer cells, such as the ability to form xenografts and the ability to escape apoptosis.
CD101-AS1 is also involved in the development of cancer cell metastasis. It has been shown to promote the migration of cancer cells, both in vitro and in vivo. This ability of CD101-AS1 to promote cancer cell migration makes it an attractive target for small molecule inhibitors.
CD101-AS1 as a drug target
CD101-AS1 is an attractive target for small molecule inhibitors due to its unique structure and function. It has a small and simple monoclonal antibody (mAb) interface, which makes it easy to target. CD101-AS1 also has a single transmembrane domain, which makes it easy to synthesize and purify.
CD101-AS1 has been shown to be a validated drug target with potential for the treatment of various cancers. For example, studies have shown that inhibitors of CD101-AS1 have the potential to treat various types of cancer, including breast, ovarian, and colorectal cancer.
CD101-AS1 as a biomarker
In addition to its potential as a drug target, CD101-AS1 has also been shown to be a potential biomarker for cancer. Its expression has been shown to be associated with cancer progression and poor prognosis. This makes CD101-AS1 an attractive target for cancer diagnostic and prognostic studies.
CD101-AS1 has also been shown to be involved in the development of cancer-related inflammation. Its expression has been shown to be associated with cancer-related inflammation, which can contribute to the development of cancer and the progression of cancer. This makes CD101-AS1 an attractive target for cancer-related inflammation targeting strategies.
Conclusion:
CD101-AS1 is a unique protein that has been shown to function as an oncogene in the development of cancer. Its simple and monoclonal antibody interface makes it an attractive target for small molecule inhibitors. Its role in cancer stem cell formation and cancer cell migration makes it an attractive target for the treatment of various cancers. Its expression has also been shown to be associated with cancer-related inflammation, which can contribute to the development and progression of cancer.
CD101-AS1 is a promising drug target and biomarker for cancer treatment. Further research is needed to fully understand its role in cancer development and treatment.
Protein Name: CD101 Antisense RNA 1
The "CD101-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD101-AS1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A | CD1B | CD1C | CD1D | CD1E | CD2 | CD200 | CD200R1 | CD200R1L | CD207 | CD209 | CD22 | CD226 | CD24 | CD244 | CD247 | CD248 | CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1
